BioStock: Curasight plans further strategic advancement

Celebrating one year as a listed company, Curasight has no plans on settling in. On the contrary, in their Q3 report, the company talks about further strategic advancements to fully realise the potential of their theranostics technology. Ulrich Krasilnikoff, CEO of Curasight, foresee an interesting news flow that will include several key value inflection points for the year to come.

Read the full article at biostock.se:

https://www.biostock.se/en/2021/11/curasight-plans-further-strategic-advancement/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se